Canaccord Genuity Maintains Buy on Doximity, Lowers Price Target to $30

Doximity, Inc. Class A

Doximity, Inc. Class A

DOCS

0.00

Canaccord Genuity analyst Richard Close maintains Doximity (NYSE: DOCS) with a Buy and lowers the price target from $34 to $30.